title: 1α,25-Dihydroxyvitamin D3 and its analogs as modulators of human dendritic cells: a comparison dose-titration study.
abstract: The biologically active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), presents pronounced immunomodulatory effects, mainly mediated through its actions on different immune cells such as dendritic cells (DC) and T lymphocytes. Because of the high concentrations needed to obtain immune effects, a major limitation in using 1α,25(OH)2D3 in clinical immune therapy is its calcemic side effects. TX527 (19-nor-14,20-bis-epi-23-yne-1α,25(OH)2D3) is a structural 1α,25(OH)2D3 analog showing reduced calcemic activity with maintained immunomodulatory effects in vitro and in vivo. The aim of the present study was to establish the relative potency of TX527 versus the parent molecule as an immunomodulator in vitro. In this regard, we evaluated the morphology, surface marker expression and reactive oxygen species (ROS) production in in vitro-generated human DCs treated with TX527 or 1α,25(OH)2D3 at different concentrations. Human CD14(+) monocytes were differentiated toward immature DCs, in the presence or absence of 1α,25(OH)2D3 or TX527 in a dose range from 10(-7)M to 10(-10)M. Mature DCs (mDC) were obtained after exposure of cells to LPS/interferon (IFN) γ or cluster of differentiation (CD) 40 ligand (L). Both compounds potently inhibited down-regulation of the monocytic marker CD14 in mDCs. Interestingly, CD80 and HLA-DR were down-regulated after TX527 treatment, whereas this effect was lost when using 1α,25(OH)2D3 at the lowest concentration (10(-10)M). ROS production was especially induced in TX527-treated DCs, without any adverse effects on cell survival. Finally, this altered DC surface phenotype was accompanied by typical morphological features, with control cells forming large clusters of non-adherent cells, whereas TX527 and, to a lesser extent, 1α,25(OH)2D3-modulated cells yielding small clusters of mostly adherent spindle-shaped cells. This more pronounced immune potential in vitro combined with the previously shown decreased side effects on calcium and bone metabolism, makes TX527 a promising 1α,25(OH)2D3 analog for in vivo applications in autoimmune diseases and transplantation. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
authors.affiliation: Laboratory for Clinical and Experimental Endocrinology (LEGENDO), University Hospital Gasthuisberg, KU Leuven, Herestraat 49, Box 902, B-3000 Leuven, Belgium.
authors.forename: Gabriela Bomfim
authors.initials: GB
authors.lastname: Ferreira
authors.forename: Lut
authors.initials: L
authors.lastname: Overbergh
authors.forename: Annemieke
authors.initials: A
authors.lastname: Verstuyf
authors.forename: Chantal
authors.initials: C
authors.lastname: Mathieu
mesh_terms: D000480:Alkynes / Q000008:administration & dosage; D018122:B7-1 Antigen / Q000378:metabolism; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002454:Cell Differentiation / Q000187:drug effects; D002762:Cholecalciferol / Q000008:administration & dosage; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D012062:Relative Biological Effectiveness
chemical_list: D000480:Alkynes; D018122:B7-1 Antigen; D006684:HLA-DR Antigens; D007155:Immunologic Factors; D018950:Lipopolysaccharide Receptors; D017382:Reactive Oxygen Species; C409043:inecalcitol; D002762:Cholecalciferol; D002117:Calcitriol